#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Semaglutide After Pancreatitis: A Case
A new case report describes semaglutide controlling refractory hypertriglyceridemia after six pancreatitis episodes.
Semaglutide and Limb Events: What We Know
A new editorial asks whether semaglutide's cardiovascular benefit now extends to limb outcomes in peripheral artery disease.
Semaglutide and Postmenopausal Bleeding
A new case report ties semaglutide to postmenopausal bleeding, but proving cause and effect from one patient is another matter.
WIN-IND: Intas Semaglutide Trial
WIN-IND found similar 24-week HbA1c changes with Intas and reference semaglutide, but its non-inferiority rule needs clarification.
GLP-1 Drugs and Biological Aging
A 2026 review examines whether GLP-1 receptor agonists could support healthier aging and where the evidence still stops short.
GLP-1 and PCOS: Reading a New Letter
A 2026 letter raises a possible GLP-1 and PCOS association, but genetic and reporting evidence cannot establish cause or guide treatment.
GLP-1 use before bariatric surgery
A matched retrospective study linked prior GLP-1RA or tirzepatide use to lower recorded early cardiorenal events after bariatric surgery.
What four months of semaglutide can show
A personal four-month timeline can document experience, but it cannot replace the controlled outcomes, safety data, or context of a semaglutide trial.
Semaglutide, weight loss and body image
Semaglutide trials measure weight and health outcomes. They cannot promise confidence, happiness, or a particular body-image result.
GLP-1 Patient Experiences in Jeddah
A survey in three Jeddah hospitals recorded patient concerns about GLP-1 medicines, but its cross-sectional design cannot establish causation.
Oral Semaglutide: A 25-Person Readout
A 25-person Japanese study linked oral semaglutide with lower energy intake, weight and body fat after three months, with key muscle caveats.
Semaglutide ASCVD cost model
A US veteran model found lifetime semaglutide added 1.31 QALYs but cost $118,996 per QALY at an assumed $14,000 annual price.